BusinessMedical Marijuana, Inc. Portfolio Investment Company, Kannalife Sciences, Inc.’s New Cannabis-Derived Compound KLS-13019 Covered by Reuters, Kannalife Explores IPO This YearBy Nasdaq OMXFeb 26, 2016, 2:00 PM UTC
BusinessMedical Marijuana, Inc. Portfolio Investment Company, Kannalife Sciences, Inc. Receives Publication Through American Chemical Society for KLS-13019, a Novel Cannabidiol-Derived Target Drug Candidate for Hepatic EncephalopathyBy Nasdaq OMXFeb 18, 2016, 2:00 PM UTC
BusinessKannalife Sciences Announces Publication of “Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, With Improved Potency, Safety and Permeability”By Nasdaq OMXFeb 16, 2016, 4:16 PM UTC
BusinessKannalife Sciences Announces Publication of “Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, With Improved Potency, Safety and Permeability”By Nasdaq OMXFeb 16, 2016, 4:16 PM UTC
